Merrill stops coverage of Qiagen

Merrill Lynch analyst Erica Whittaker is not longer covering Qiagen due to "a reallocation of resources." The company's reported sales beat the analyst's forecast and met consensus expectations. Shares of the Venlo, The Netherlands-based biotechnology company were down 23 cents, or 1.51%, at $15.03. (Nasdaq: QGEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.